COSCIENS Biopharma Inc (CSCI)

[livendi]

alot of factors contributed to that,covid,ins in usa being cheap,it will get better with new licensing deals and with time but the key is pedi approval for test which is for an unmet need,no way to test kids,also the other uses for macrilen is another big key,u know its in phase 3 in usa for tbi and cancer cachexia and preclinicals for lou gehrigs disease,a little more patience is what we need although it does suck seeing it go down,just a matter of time though as way too many different catalysts coming imo,god blessall and good luck to us